摘要
目的:探讨3种给药方案治疗原发性高血压的经济学效果。方法:筛选我院轻、中度原发性高血压患者住院病例84例,根据不同的治疗方案分为3组,A组:依那普利,B组:氢氯噻嗪+缬沙坦,C组:卡托普利+非洛地平,运用费用-效果分析方法进行评价。结果:A、B、C组总有效率分别为80.0%、84.0%、87.2%(P>0.05);不良反应发生率分别为10.0%、8.0%、5.1%(P>0.05);费用分别为702.15元、683.54元、695.06元。通过分析比较可知B、C两方案费用效果相当,且均优于A方案,但C方案更具优势。结论:药物经济学在优化治疗方案,指导合理用药,减轻患者经济负担,提高社会经济效益和指导新药开发方面具有重要作用。
OBJECTIVE： To discuss the economic effects of 3 therapeutic projects for primary hypertension. METHODS： 69 patients files of mild and moderate prima-hypertension patients were selected and divided into 3 groups according to therapeutic projects ： （A） enalapril; （ B ） valsartan ＋ hydrochlorothiazide; （ C ） captopril ＋ felodipine. RESULTS：Data were evaluated using the pharmacoeconomic cost- effectiveness analysis. The total efficiency rates of A, B and C group were 80.0 %, 84.0 %, and 87.2 % （ P 〉 0.05） respectively ; adverse drug reaction rates of those groups were 10.0 %, 8.0 % and 5.1% （ P 〉 0.05）, respectively; the costs of those groups are 702.15 yuan, 683.54 yuan and 695.06 yuan, respectively. The costs and efficiencies of both project B and C are similar, and they are both better than project A. Moreover, project C has obvious predominance. CONCLUSION：The pharmacoeconomics plays an important role in guiding physicians and pharmacists to choose the best therapeutic regimen in making clinical decision, in gaining the maximal benefits with the minimal costs, and in guiding new drug development.
出处
《中国医院用药评价与分析》
2007年第5期371-373,共3页
Evaluation and Analysis of Drug-use in Hospitals of China
关键词
费用效果分析
药物经济学
原发性高血压
Cost - effectiveness analysis
Pharmacoeconomics
Primary hypertension
